Rigel Pharmaceuticals, Incorporated

Torch Therapeutics

Kristen Baltgalvis

Todd M Kinsella

Ramesh Bhatt

Donald G Payan

This invention describes the design of bispecific antibodies that function as conditionally effective therapeutics by binding to a functionally silent epitope on one component of a targeted signaling complex and simultaneously binding to a second protein, whose expression or accessibility is cell- or disease environment-specific, and whose antibody-driven proximity to the signaling complex leads to an alteration of signal transduction.

Method of using a bispecific antibody to conditionally inhibit a receptor signaling complex

The present disclosure provides antibodies that specifically bind to and block signaling by ACVR2A, i.e., ACVR2A but not ACVR2B, as well as methods for using the same. The antibodies may be used for the treatment of a number of conditions associated with muscle atrophy, as well as other conditions.

Growing community of inventors

Poway, CA, United States of America

Kristen Baltgalvis